Yesterday the JPMorgan healthcare conference was progressing and OPTR presented their story.  I think the possible label additions will add to their potential, a natural progression to new drugs.  There could be some buzz from that. 

Today the share price is up considerably, compared to the recent trading range.  The interesting part is that the volume is down, and I suspect the shorts are not shorting or we would see higher volume and the usual volatility.  So we have to wait for them to show their stuff. :)